Together, our data demonstrate that SMARCA4 loss in NSCLC results in reduced cyclin D1 expression, which underlies the synthetic lethal interaction between SMARCA4 deficiency and CDK4/6 inhibition. The gene discussed is CDK4; the disease is non-small cell lung carcinoma.